Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282138 · ClinicalTrials.gov registry record · Phase 4
Assessment of Alcon's Ocular Image Quantification System
A Phase 4 study of Allergic Conjunctivitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT01282138 is a Phase 4 study of Allergic Conjunctivitis that has completed, run by Alcon Research. The registered enrollment target is 13 participants, below the 134-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01282138, a Phase 4 study of Allergic Conjunctivitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
Conditions Studied
Interventions
- DRUG Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
- OTHER Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)
Study Locations (1)
Texas
- Contact Alcon Call Center for Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282138
The ClinicalTrials.gov registry entry for NCT01282138 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (90% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol) is the first listed.
NCT01282138 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01282138 about?
NCT01282138 is a clinical study titled "Assessment of Alcon's Ocular Image Quantification System". The purpose of this study was to evaluate ocular responses with different allergen provocation methods.
What is the current status of trial NCT01282138?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2010-12. Estimated completion is 2011-03.
What conditions does trial NCT01282138 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01282138?
The interventions under investigation include: Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol) (DRUG), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II) (OTHER).
Who is sponsoring clinical trial NCT01282138?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01282138 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 4
-
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
COMPLETED · Phase 4
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.